Table 2 miR-503 expression and mRS in acute and chronic phase, NIHSS score, history of hypertension and hyperlipidemia, using antihypertensive and antiplatelet drugs, different clinical manifestations and stroke subtypes in all groups

miR-503 expression (acute)

3.3 ± 2.1

1.9 ± 1.5

2.5 ± 1.8

1.1 ± 0.4

P = 0.045

(I), (II): p = 0.02, (II), (III): p = 0.3

(I), (III): p = 0.2 (II), (IV): p = 0.4

(I). (IV): p = 0.016 (III), (IV): p = 0.1

miR-503 expression (chronic)

1.2 ± 0.6

1.3 ± 0.4

2.5 ± 1.8

1.1 ± 0.4

P = 0.009

(I), (II): p = 0.8, (II), (III): p = 0.005

(I), (III): p = 0.004 (II), (IV): p = 0.7

(I), (IV): p = 0.8

NIHSS score

12.2 ± 5.2

11.8 ± 5.3

–

–

p > 0.05

mRS acute

3.4 ± 1.2

3.3 ± 1.3

–

–

p > 0.05

mRS chronic

2 ± 1.5

3.2 ± 1.9

–

–

p > 0.05

Hypertension (Y)

11 (84.6%)

13 (72.2%)

3 (25%)

2 (40%)

p > 0.05

Hyperlipidemia (Y)

5 (38.5%)

9 (50%)

4 (33.3%)

2 (40%)

p > 0.05

Antihypertensive drug

10 (66.6%)

13 (72.2%)

3 (25%)

2 (40%)

p > 0.05

Antiplatelet drug

6 (46.2%)

11 (47.8%)

–

–

p > 0.05

Clinical manifestation

–

–

p > 0.05

 Altered consciousness

2 (13.3%)

7 (38.8%)

 Diplopia/dysarthria/facial paralysis

10 (76.9%)

8 (44.4%)

 Hemiparesis/hemisensory deficit

10 (76.9%)

13 (72.2.%)

Stroke subtype

p > 0.05

 LVA

6 (40%)

10 (52.6%)

 SVA

8 (53.3%)

6 (31.6%)

 Cardioembolic

1 (6.7%)

3 (15.8%)